NICE Appraisal Strikes Down Three Ovarian Cancer Drugs In The U.K.
This article was originally published in The Pink Sheet Daily
As the result of a multiple technology appraisal from Britain’s U.K.’s reimbursement watchdog, NICE, three ovarian cancer drugs will disappear from the publicly funded NHS.
You may also be interested in...
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.